Alnylam Pharma (ALNY) Misses Q2 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $225.10 -2.43%
Revenue Growth %: +14.5%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Revenue Growth %: +14.5%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($2.03), $0.42 worse than the analyst estimate of ($1.61). Revenue for the quarter came in at $224.82 million versus the consensus estimate of $255.87 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Getty Realty (GTY) Tops Q3 EPS by 5c
- First Bancorp. (FBNC) Tops Q3 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
